Klotho Neurosciences' Exciting New Developments in Gene Therapy
Klotho Neurosciences, Inc. (NASDAQ: KLTO) has announced a significant step forward in their mission to combat amyotrophic lateral sclerosis (ALS). The company is focused on advancing the manufacturing and process development for their investigational gene therapy, KLTO-202. This innovative approach could provide hope for those suffering from this devastating condition.
Understanding the Role of the Alpha-Klotho Gene
At the core of KLTO-202 is a unique RNA splice variant of the human alpha-Klotho gene. This gene, licensed from a prestigious research institution, encompasses a variety of patents and intellectual properties necessary for developing cutting-edge gene therapy. The alpha-Klotho gene plays a vital role throughout the human body, particularly in its influence on cellular functions.
The full-length protein known as membrane-bound Klotho (m-KL) is primarily found in kidney cells, while a smaller variant, the secreted alpha-Klotho (s-KL), is concentrated in neurons of the brain and spinal cord. Studies conducted by Klotho Neurosciences over the past two years have shown that amplifying s-KL levels can lead to outstanding therapeutic results. These studies, with contributions from animal models, have successfully demonstrated improvements in conditions mimicking ALS and other neurodegenerative diseases.
Key Milestones in the Development of KLTO-202
The road ahead for KLTO-202 is both structured and ambitious. Klotho Neurosciences anticipates completing the manufacturing process and necessary development work within eight months. Following this, there will be engagements with regulatory bodies, including the FDA, to finalize safety studies and submit an investigational new drug application (IND).
In addition, the company is preparing clinical sites for the Phase I/II studies, aiming to initiate these important trials by the third quarter of next year. This plan also includes collaborating with contract research organizations (CROs) to streamline the process, allowing the company to focus its resources efficiently.
Leadership Insights on the Path Forward
Joseph Sinkule, the CEO and founder of Klotho Neurosciences, expressed excitement regarding recent fundraising victories which enable the company to advance its crucial work. He highlighted their innovative production method for the AAV vector, which is essential for delivering the s-KL gene directly into motor neurons, cells that are severely impacted by ALS.
The ultimate goal is to increase local concentrations of s-KL in these neurons to mitigate the damage that leads to muscle paralysis and associated complications. Joseph emphasized the urgency and importance of this work, as ALS progresses rapidly and often results in severe loss of mobility and independence within a mere few years of diagnosis.
About Klotho Neurosciences
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is at the forefront of biogenetics, dedicated to developing transformative cell and gene therapies that target neurodegenerative disorders, including ALS, Alzheimer's, and Parkinson's disease. The company’s innovative approach leverages the potential of the anti-aging Klotho gene and focuses on providing effective treatment solutions. Their portfolio includes advanced therapeutics in gene therapy, DNA, and RNA applications, guided by a team of seasoned professionals experienced in biopharmaceutical development.
Investor Relations and Corporate Communications
For further information regarding investor relations, please reach out to Jeffrey LeBlanc, CFO of Klotho Neurosciences.
Frequently Asked Questions
What is KLTO-202?
KLTO-202 is an investigational gene therapy developed by Klotho Neurosciences aimed at treating ALS.
What is the alpha-Klotho gene?
This gene produces proteins that benefit cellular health, particularly in the brain and spinal cord, providing neuroprotective effects.
How does Klotho Neurosciences plan to move forward?
They aim to complete the manufacturing and development of KLTO-202 soon and prepare for clinical trials with FDA collaborations.
Who is leading Klotho Neurosciences?
Joseph Sinkule is the CEO and founder, driving the company's efforts in gene therapy innovation.
What are the future prospects for KLTO-202?
The company is committed to advancing the therapy through clinical trials and believes it could significantly impact ALS treatment.
